Los puntos clave no están disponibles para este artículo en este momento.
This economic evaluation estimates annual total US spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023.
Share your take
Add a clinician perspective alongside expert commentary.
Tsipas et al. (Wed,) studied this question.